ARQT vs. RVMD, GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, and TGTX
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
Arcutis Biotherapeutics vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.
Revolution Medicines has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -35.40%. Revolution Medicines' return on equity of -41.78% beat Arcutis Biotherapeutics' return on equity.
94.3% of Revolution Medicines shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Arcutis Biotherapeutics has higher revenue and earnings than Revolution Medicines. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
Revolution Medicines currently has a consensus price target of $74.64, suggesting a potential upside of 54.73%. Arcutis Biotherapeutics has a consensus price target of $19.80, suggesting a potential downside of 1.25%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Revolution Medicines is more favorable than Arcutis Biotherapeutics.
In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Arcutis Biotherapeutics and 5 mentions for Revolution Medicines. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Revolution Medicines' score of 0.50 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Summary
Revolution Medicines beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARQT) was last updated on 10/13/2025 by MarketBeat.com Staff
